LOX and glycogen storage disease VI: While there was no difference in the levels of PGE2 between the clinical groups at baseline, mediators of the LOX pathway were elevated (LXA4, p=0.006 and 12-HETE, p=0.042) in cavitary disease compared to non-cavitary disease (Figure 2).